Optimizing weight loss interventions for older adults
Official title: Optimizing Telehealth-delivery of a Weight Loss Intervention in Older Adults With Multiple Chronic Conditions: A Sequential, Multiple Assignment, Randomized Trial
Run by University of North Carolina, Chapel Hill · NCT06044571 · Data updated 2026-11-12
This study is testing which weight loss program works best for older adults with obesity and health issues, comparing a medical approach to a coaching method.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 65 Years to 85 Years |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | University of North Carolina, Chapel Hill Academic / other |
| Drugs / interventions | denosumab |
| Locations | 1 site (Chapel Hill, North Carolina) |
| Status | Recruiting |
| Started | April 16, 2024 |
| Main results expected | September 1, 2027 |
| Study ends | September 1, 2027 |
| Registry record updated | February 6, 2026 |
| Trial ID | NCT06044571 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are community-dwelling adults aged 65-85 with obesity and at least two chronic medical conditions.
✕Probably not a fit
Patients over 85 years old or those residing in nursing homes or assisted living facilities may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the best initial weight loss intervention for older adults with obesity and multiple chronic conditions. Using a Sequential, Multiple Assignment, Randomized Trial (SMART) design, it will compare a prescriptive, medically-tailored intervention with a behavioral health coaching approach. Participants who do not respond to the initial intervention will be randomized to receive a combination of both strategies or switch to the alternative approach. The goal is to identify effective interventions that improve health outcomes and reduce healthcare costs for this population.
Why it matters
Potential benefit: If successful, this study could significantly enhance the health and quality of life for older adults struggling with obesity and multiple chronic conditions.
How similar studies have gone: Other studies have shown promise in using adaptive interventions for weight loss in older adults, suggesting potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria based on chart review at the time of screening (within 8 weeks of randomization): * Community-dwelling adult living independently (not a resident of a nursing home or an assisted living); * Aged 65-85 years (unclear benefits of weight loss if \>85 years) * Obesity (body mass index: ≥30 kg/m2); * English-speaking; -≥2 chronic medical conditions that require ongoing care (excluding dementia and osteoporosis as a chronic condition) - these are based on Medicare' MCC (e.g., alcohol abuse, arthritis (osteoarthritis, rheumatoid), asthma, atrial fibrillation, autism spectrum disorders, cancer (breast, colorectal, lung, prostate), chronic kidney disease, chronic obstructive pulmonary disease, depression, diabetes, drug/substance abuse, heart failure, hepatitis, Human Immunodeficiency Virus / Acquired Immunodeficiency Disease Syndrome, hyperlipidemia, hypertension, ischemic heart disease, schizophrenia/other psychotic disorders, stroke). We acknowledge that there are no fully defined definitions and hence we will be assessing MCC (or multimorbidity) in different manners; * medical clearance by PCP (Primary Care Provider) * Callahan cognitive screen ≥ 3 correct items; items (a score of three or more correct items indicates an ability to consent); * OARS (Older Americans Resources and Services)survey score of ≥12; (a score of 12 or more indicates no impairments or disability) * Readiness to change score of ≥6/10; Exclusion Criteria: Any individual who meets one or more of the following criteria will be excluded from participation based on chart review at the time of screening (within 8 weeks of randomization): * documented diagnosis in the electronic health record of dementia of any type; * documented diagnosis in the electronic health record of weight loss surgery in the past; * untreated psychiatric disorder that would impair the ability to participate (bipolar, schizophrenia) based on medical record review; * life-threatening illness; * terminal illness (e.g., palliative care, hospice patient) based on medical record review whose life expectancy is \<12 months as determined by a physician; * nursing home or hospital admission in past three months; * advanced comorbidities based on medical record review; * heart - recent hospital admission for heart failure, myocardial infarction, stroke in past 3 months, unstable disease (new york class III or IV congestive heart failure); * chronic renal failure - chronic kidney disease stage IV or V (e.g., GFR \[glomerular filtration rate\] \<30ml/min); * non-skin cancer - history of requiring active treatment in the past year; * liver failure or cirrhosis; * chronic obstructive pulmonary disease - on oxygen or requiring steroids; * weight loss contraindication as noted by the PCP; * instability of weight loss, which is greater than 5% weight loss in the past 12 weeks; * anti-obesity medications including orlistat, semaglutide, liraglutide, tirzepetide, naltrexone-bupropion and phentermine prior to initiation of study procedures; * current use of bone acting medications (e.g., raloxifene, calcitonin, parathyroid hormone during the past year, Parathyroid Hormone Analogues (PTH-analogues \[e.g., teriparatide, abaloparatide\], sclerostin) inhibitors (romosozumbab), RANK ligand inhibitors (denosumab) or bisphosphonates during the last two years; * osteoporosis by medical record (t-score -2.5 and below on hip or spine scan) or history of fragility fractures; * elective surgery in next 12 months; * recent (\<1 mo) COVID-19 infection; * current or past participation (in the past 12 months) in another weight-loss study; * Planning on moving out of the area in the next 18 months.
Where it's running
-
UNC Center for Aging and Health
Chapel Hill, North Carolina, United States Recruiting
Study contacts
- Principal investigator: John Batsis, MD — University of North Carolina, Chapel Hill
- Study coordinator: Brett R Sheppard, MA
- Email: brett_sheppard@unc.edu
- Phone: 919-423-9264
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ocular Changes in People Using Tirzepatide or Semaglutide
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Berobenatide for knee pain in adults who are overweight or with obesity
This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.
-
Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese
This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).
-
Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists
This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.